 Richard Walovitch, Ph.D. WorldCare Clinical Chief Medical Officer Visit Website |
Dr. Walovitch is chief medical officer of WorldCare Clinical. Prior to joining WCC, he served as the senior vice president of clinical research at Acusphere, Inc., vice president of preclinical and clinical research at Epix Medical, and research pharmacologist and project clinician in the Imaging Agent Group at the DuPont Merck Pharmaceutical Company. Walovitch has a doctorate in pharmacology from the University of Illinois Medical Center and a bachelor’s degree in biology from the University of Illinois. He is an author of more than 100 peer-reviewed publications, mostly in the field of medical imaging.
|
Imaging Q&A
-
What are the one or two, in your opinion, most promising novel imaging techniques emerging in Phase I and II studies, and which therapeutic areas do they have the greatest potential?Answered January 7th, 2010 by Expert:In Phase I and Phase II studies, dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI) has shown promise in studying the pathophysiology of tumors. We currently measure tumor mass shrinkage to help determine potential efficacy, but DCE-MRI actually allows us to see changes in tumor vascularity by helping to measure blood flow in tissues and provide insight into vascular morphology. And because vascularity occurs at an earlier stage in tumor treatment than does shrinkage, DCE-MRI has the potential to enable earlier assessment of the response or failure of a particular drug. The possibilities here are extremely promising so far.
Leave a reply